TRENDING TOPICS
1366 articles found for "investing"
Boston Dynamics announces Atlas humanoid robot production begins immediately, with Google DeepMind's Gemini Robotics AI powering the next generation of industrial automation.
Global investment-grade bond issuance hit a record $72 billion in the first two days of 2026 trading, signaling strong investor appetite for corporate credit despite geopolitical uncertainty.
European defense contractors surged Wednesday as Denmark announced plans to rearm Greenland following President Trump's renewed threats to annex the Arctic territory.
Circana forecasts U.S. consumer technology sales will grow just 0.2% to $112 billion in 2026, as economic pressures and a spending divide between income groups reshape the market.
A packed economic calendar featuring ISM Services PMI, JOLTS job openings, and Friday's jobs report will test market assumptions about Federal Reserve policy and economic health.
Asian stock markets retreated Wednesday after the best start to a year on record pushed the MSCI Asia Pacific Index into overbought territory with RSI above 70.
Nvidia CEO Jensen Huang revealed 'very high' demand from China for H200 AI chips as the company works to finalize export license details with U.S. government officials.
Amgen announced an $840 million deal to acquire protein degrader startup Dark Blue Therapeutics, betting on next-generation drug technology that could transform cancer treatment.
The S&P 500 climbed to 6,944 as a new survey reveals 90% of investors plan to own AI stocks this year. Nvidia and Broadcom lead the pack as market breadth improves.
Alumis shares nearly doubled after the biotech reported positive Phase 3 results for its TYK2 inhibitor in moderate-to-severe psoriasis. The drug showed superior efficacy to existing treatments.
The FDA approved Novo Nordisk's oral formulation of Wegovy, making it the first obesity pill based on GLP-1 technology. The approval gives Novo a head start over rival Eli Lilly.
Amgen announced an $840 million deal to acquire protein degrader startup Dark Blue Therapeutics, betting on next-generation drug technology that could transform cancer treatment.